USPTO serial 99092562
MYOFORMIN
Reviewed by CopyMark Law Group
Status 731Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- DUBOIS, SUSAN L
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with MYOFORMIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Rochester, MN, US
Rochester, MN, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Erica M Hines
Erica M Hines Heslin Rothenberg Farley & Mesiti PC5 Columbia CircleAlbany, NY 12203United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Pharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, bariatric surgery, or conditions that accompany treatment with weight loss medications; or conditions or complications associated with any of the foregoing; Nutraceuticals for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Nutraceuticals for use as a dietary supplement for inhibiting muscle atrophy, inhibiting sarcopenia, inhibiting muscular weakness, inhibiting fatigue, inhibiting obesity, inhibiting diabetes, promoting muscle health, promoting muscular strength | PARTIALLY PAID | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 10, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 10, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 10, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 29, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 28, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 28, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 28, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 11, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 25, 2025 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Oct 23, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 16, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Sep 16, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 16, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 10, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 20, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 19, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 19, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 19, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 19, 2025 | NWAP | NEW APPLICATION ENTERED | — |